Linda M Styer1, Thomas T Miller2, Monica M Parker2. 1. Bloodborne Viruses Laboratory, Wadsworth Center, New York State Department of Health, Albany, NY 12208, United States; Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, NY 12201, United States. Electronic address: lms24@health.state.ny.us. 2. Bloodborne Viruses Laboratory, Wadsworth Center, New York State Department of Health, Albany, NY 12208, United States.
Abstract
BACKGROUND: Human immunodeficiency virus type 2 (HIV-2) is distantly related to the more widespread HIV-1. Although HIV-2 infection is rare in the U.S., cases are concentrated in the Northeast. No FDA-approved HIV-2 viral load assays exist. A clinically validated laboratory-developed assay is currently available in the U.S., however it is not currently approved for use on New York State patients. OBJECTIVE: To develop a sensitive viral load assay to quantify HIV-2 RNA in plasma and to validate it for clinical use. METHODS: The real-time RT-PCR assay simultaneously amplifies HIV-2 and a whole virus internal control, added during the lysis step. Two extraction volumes can be used. Results are reported in HIV-2 RNA International Units (IU). RESULTS: The assay has a limit of detection of 7 IU/mL and a lower limit of quantification of 29 IU/mL. The assay detects multiple strains of HIV-2 group A and B and generates reproducible results. Samples exchanged with a comparator laboratory produced similar viral load results, with 74% of positives differing by <0.5 log10 IU/mL. To date, we have tested 52 clinical specimens from 25 individuals. Twenty-eight (54%) specimens had measurable HIV-2 viral loads (range: 1.63-5.14 log10 IU/mL), 10 (19%) were positive but not quantifiable, and 14 were negative. HIV-2 RNA was detected in at least one specimen from 19 of 25 (76%) individuals tested. CONCLUSIONS: We developed a sensitive and accurate HIV-2 viral load assay. Validation data indicate the assay is suitable for clinical use and its availability in New York State will improve clinical monitoring of HIV-2 infected patients.
BACKGROUND:Human immunodeficiency virus type 2 (HIV-2) is distantly related to the more widespread HIV-1. Although HIV-2 infection is rare in the U.S., cases are concentrated in the Northeast. No FDA-approved HIV-2 viral load assays exist. A clinically validated laboratory-developed assay is currently available in the U.S., however it is not currently approved for use on New York State patients. OBJECTIVE: To develop a sensitive viral load assay to quantify HIV-2 RNA in plasma and to validate it for clinical use. METHODS: The real-time RT-PCR assay simultaneously amplifies HIV-2 and a whole virus internal control, added during the lysis step. Two extraction volumes can be used. Results are reported in HIV-2 RNA International Units (IU). RESULTS: The assay has a limit of detection of 7 IU/mL and a lower limit of quantification of 29 IU/mL. The assay detects multiple strains of HIV-2 group A and B and generates reproducible results. Samples exchanged with a comparator laboratory produced similar viral load results, with 74% of positives differing by <0.5 log10 IU/mL. To date, we have tested 52 clinical specimens from 25 individuals. Twenty-eight (54%) specimens had measurable HIV-2 viral loads (range: 1.63-5.14 log10 IU/mL), 10 (19%) were positive but not quantifiable, and 14 were negative. HIV-2 RNA was detected in at least one specimen from 19 of 25 (76%) individuals tested. CONCLUSIONS: We developed a sensitive and accurate HIV-2 viral load assay. Validation data indicate the assay is suitable for clinical use and its availability in New York State will improve clinical monitoring of HIV-2 infectedpatients.
Authors: Luke A Wiley; Erin R Burnight; Arlene V Drack; Bailey B Banach; Dalyz Ochoa; Cathryn M Cranston; Robert A Madumba; Jade S East; Robert F Mullins; Edwin M Stone; Budd A Tucker Journal: Hum Gene Ther Date: 2016-07-11 Impact factor: 5.695
Authors: Ming Chang; Audrey J S Wong; Dana N Raugi; Robert A Smith; Annette M Seilie; Jose P Ortega; Kyle M Bogusz; Fatima Sall; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb; Robert W Coombs Journal: J Clin Virol Date: 2016-11-23 Impact factor: 3.168
Authors: Didier K Ekouévi; Véronique Avettand-Fènoël; Boris K Tchounga; Patrick A Coffie; Adrien Sawadogo; Daouda Minta; Albert Minga; Serge P Eholie; Jean-Christophe Plantier; Florence Damond; François Dabis; Christine Rouzioux Journal: PLoS One Date: 2015-06-25 Impact factor: 3.240
Authors: Linda L Jagodzinski; Ying Liu; Holly R Hack; Catherine Kibirige; Sheila A Peel; Mark M Manak Journal: PLoS One Date: 2014-05-05 Impact factor: 3.240
Authors: Christopher Z Abana; Kwamena W C Sagoe; Evelyn Y Bonney; Edward K Maina; Ishmael D Aziati; Esinam Agbosu; Gifty Mawuli; Linda M Styer; Koichi Ishikawa; James A M Brandful; William K Ampofo Journal: Medicine (Baltimore) Date: 2019-02 Impact factor: 1.817
Authors: Selly Ba; Ndeye Mery Dia-Badiane; Stephen Edward Hawes; Louise Fortes Deguenonvo; Fatima Sall; Cheikh Tidiane Ndour; Khadim Faye; Fatou Traoré; Macoumba Touré; Marie Pierre Sy; Dana Noelle Raugi; Nancy Berenice Kiviat; Robert Alexander Smith; Moussa Seydi; Papa Salif Sow; Geoffrey Scott Gottlieb Journal: Pan Afr Med J Date: 2019-07-18
Authors: Sara A Byron; Kendall R Van Keuren-Jensen; David M Engelthaler; John D Carpten; David W Craig Journal: Nat Rev Genet Date: 2016-03-21 Impact factor: 53.242